Table 1.
Baseline of patients' characteristics (n = 51).
| Characteristics | Total (n = 51) | Group A (n = 24) | Group B (n = 27) | P |
|---|---|---|---|---|
| Age (year) | 0.781 | |||
| Median | 78 | 78 | 77.5 | |
| Range | 75–82 | 75–80 | 75–82 | |
| Sex | 0.778 | |||
| Male | 33 | 15 | 18 | |
| Female | 18 | 9 | 9 | |
| Performance status | 0.540 | |||
| 0 | 16 | 9 | 7 | |
| 1 | 26 | 12 | 14 | |
| 2 | 9 | 3 | 6 | |
| Time to liver metastases | 0.546 | |||
| Synchronous | 21 | 9 | 7 | |
| Metachronous | 30 | 15 | 20 | |
| Site of primary cancer | 0.404 | |||
| Colon | 28 | 10 | 15 | |
| Rectum | 23 | 14 | 12 | |
| Lobulor involvement | 0.264 | |||
| Bilobar | 27 | 15 | 12 | |
| Unilobar | 24 | 9 | 15 | |
| Number of lesions | 0.555 | |||
| ≤.5 | 19 | 7 | 12 | |
| > 5 | 32 | 17 | 15 | |
| Baseline of CEA | 0.405 | |||
| > 200 ng/ml | 22 | 12 | 10 | |
| < 200 ng/ml | 29 | 12 | 17 |
Abbreviations: CEA, carcinoembryonic antigen; LDH, lactate dehydrogenase
Group A: hepatic arterial infusion of fluorouracil + capecitabine; Group B: capecitabine alone